


How should we evaluate efficacy in modern haemophilia care?

SAVE THE DATE

1st February 2017, 14:00–15:30
Paris Marriott Rive Gauche Hotel &
Conference Center Paris, France

Meeting Co-chairs:
Martin Schulz (Pfizer)
Claude Négrier (France)



*Fondation Louis Vuitton
Art museum and cultural centre*

Agenda

- 14:00 **Welcome and introduction**
Martin Schulz (Pfizer), Claude Négrier (France)
- 14:05 **How should we evaluate efficacy in haemophilia A:
Compliance with treatment?**
Giovanni Di Minno (Italy)
- 14:25 **How should we evaluate efficacy in haemophilia:
Genotype / phenotype?**
Andreas Tiede (Germany)
- 14:45 **How should we evaluate efficacy in haemophilia B:
Pharmacokinetics and trough levels?**
Gerry Dolan (UK), Charles Hay (UK)
- 15:05 **How do we measure efficacy in an era of gene therapy?**
Katherine High (USA)
- 15:25 **Meeting summary**
Martin Schulz (Pfizer)
- 15:30 **Meeting close**